{"id":"W2003305754","doi":"10.1016/j.ygyno.2008.02.009","title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia","year":2008,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Fallopian tube cancer; Gastrointestinal perforation; Ovarian cancer; Internal medicine; Tolerability; Clinical endpoint; Nausea; Erlotinib; Perforation; Surgery; Vomiting; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Adverse effect; Clinical trial; Peritonitis; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001821684,0.0002148505,0.0008857982,0.00005606836,0.0002455541,0.000003661951,0.00006992002,0.0001891285,0.00006413279],"category_scores_gemma":[0.0002325826,0.0001289013,0.00006567127,0.0001075661,0.0006834026,0.00002910778,0.0001170208,0.0001554225,1.939531e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002777071,"about_ca_system_score_gemma":0.000824276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008965943,"about_ca_topic_score_gemma":0.0002072696,"domain_scores_codex":[0.9985469,0.0001156732,0.000511576,0.0004030908,0.0001607324,0.0002620085],"domain_scores_gemma":[0.9984857,0.0006376466,0.0003622762,0.0002289575,0.0001453054,0.0001401376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3542226,0.01874244,0.3286905,0.0007765744,0.001528758,0.00006436816,0.002979249,0.00001295741,0.0002006115,0.0005876461,0.00186924,0.290325],"study_design_scores_gemma":[0.3227789,0.04948718,0.6038777,0.0001096139,0.0007664881,0.00005526563,0.00005306624,0.0000408717,0.00009496423,0.00003047179,0.02254887,0.0001566179],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913833,0.00104364,0.000005961576,0.002327838,0.0002922323,0.004174292,0.0004923443,0.00001356825,0.0002668431],"genre_scores_gemma":[0.9960609,0.002144577,0.0008480917,0.0003002929,0.00006937243,0.0004614117,0.00005934304,0.00001539955,0.00004059947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2901684,"threshold_uncertainty_score":0.5256444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02357263650907375,"score_gpt":0.3040609768563782,"score_spread":0.2804883403473045,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}